Payment overview · 2025
General Payments
$210.70
10 reported records · 5 companies
Healthcare provider profile · identity verified
Eli T. James, MD
Allopathic & Osteopathic Physicians|Family Medicine · LANCASTER, WI · NPI 1669959441
Verified facts
What the public records show
CMS Open Payments records show Eli T. James, MD received $210.70 in general payments during 2025 across 10 reported records.
PFIZER INC. accounted for 32.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Jardiance, Rexulti.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $68.16 | 32.4% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $55.34 | 26.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $36.31 | 17.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $25.98 | 12.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.91 | 11.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $210.70 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $55.34 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $50.52 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $50.52 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $36.31 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $25.98 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 11 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 59 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 74 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 14 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
74 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
147 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 298 | 73 |
| Atorvastatin Calcium | Atorvastatin Calcium | 268 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 203 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 183 | 40 |
| Potassium Chloride | Potassium Chloride | 164 | 51 |
| Omeprazole | Omeprazole | 150 | 48 |
| Eliquis | Apixaban | 147 | 24 |
| Tramadol Hcl | Tramadol Hcl | 141 | 37 |
| Amlodipine Besylate | Amlodipine Besylate | 131 | 39 |
| Losartan Potassium | Losartan Potassium | 116 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 22 |
| Lisinopril | Lisinopril | 107 | 32 |
| Gabapentin | Gabapentin | 106 | 17 |
| Lorazepam | Lorazepam | 106 | 18 |
| Mirtazapine | Mirtazapine | 95 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 26 |
| Simvastatin | Simvastatin | 91 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 90 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 83 | 18 |
| Metformin Hcl | Metformin Hcl | 81 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | 24 |
| Warfarin Sodium | Warfarin Sodium | 79 | 15 |
| Cephalexin | Cephalexin | 76 | 34 |
| Xarelto | Rivaroxaban | 75 | 15 |
| Rexulti | Brexpiprazole | 74 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 73 | 22 |
| Celecoxib | Celecoxib | 71 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 71 | 23 |
| Valsartan | Valsartan | 70 | 13 |
| Rytary | Carbidopa/Levodopa | 69 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 35 |
| Alendronate Sodium | Alendronate Sodium | 68 | 15 |
| Allopurinol | Allopurinol | 68 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 16 |
| Glipizide Er | Glipizide | 65 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 17 |
| Jardiance | Empagliflozin | 59 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | suppressed |
| Carvedilol | Carvedilol | 58 | 18 |
| Mounjaro | Tirzepatide | 58 | suppressed |
| Ozempic | Semaglutide | 58 | 12 |
| Fentanyl | Fentanyl | 56 | suppressed |
| Dexamethasone | Dexamethasone | 55 | 44 |
| Bupropion Xl | Bupropion Hcl | 53 | 13 |
| Clonazepam | Clonazepam | 53 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 23 |
| Nifedipine Er | Nifedipine | 48 | suppressed |
| Ondansetron Odt | Ondansetron | 48 | 33 |
| Baclofen | Baclofen | 45 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 13 |
| Alprazolam | Alprazolam | 43 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 43 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 43 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Glipizide | Glipizide | 40 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 36 | suppressed |
| Sucralfate | Sucralfate | 36 | 18 |
| Cefdinir | Cefdinir | 35 | 33 |
| Ezetimibe | Ezetimibe | 35 | 11 |
| Spironolactone | Spironolactone | 35 | 13 |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 11 |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Latanoprost | Latanoprost | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 27 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 23 |
| Montelukast Sodium | Montelukast Sodium | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Prednisone | Prednisone | 24 | 14 |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 21 |
| Loperamide | Loperamide Hcl | 23 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 22 | 19 |
| Bumetanide | Bumetanide | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Budesonide | Budesonide | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $210.70 · 10 records | PFIZER INC. | ABRYSVO, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, JARDIANCE, NURTEC ODT, PREVNAR 20, REXULTI, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error